Business
RxSight, Inc. Appoints Raymond W. Cohen to Its Board of Directors
ALISO VIEJO, Calif., Aug. 04, 2025 (GLOBE NEWSWIRE) -- (Nasdaq: RXST) – RxSight, Inc., an ophthalmic medical device company dedicated to providing high-quality customized vision to patients following cataract surgery, today announced the appointment of Raymond W. Cohen to its Board of Directors. “We are thrilled to welcome Raymond W. Cohen to the RxSight Board of Directors,” said J. Andy Corley, Chairman of the Board at RxSight. “Ray’s extensive track record in leading and scaling medical techno
About this update from Inspiremd Inc.
[{"type":"image","alt":"RxSight, Inc.","displaySize":"","headline":null,"caption":"RxSight, Inc.","className":"","disableSlideshowImg":false,"size":{"original":{"width":300,"height":92,"url":"https://media.zenfs.com/en/globenewswire.com/b21b6ecb1a46af6790a9c276a59298b4"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/RlZbsYuiF8.V1Nc6BC4.Lw--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTEyOTtjZj13ZWJw/https://media.zenfs.com/en/globenewswire.com/b21b6ecb1a46af6790a9c276a59298b4","width":300,"height":92}},"lazy":false},{"type":"text","content":"ALISO VIEJO, Calif., Aug. 04, 2025 (GLOBE NEWSWIRE) -- (Nasdaq: RXST) – RxSight, Inc., an ophthalmic medical device company dedicated to providing high-quality customized vision to patients following cataract surgery, today announced the appointment of Raymond W. Cohen to its Board of Directors.","length":301,"tagName":"p"},{"type":"text","content":"“We are thrilled to welcome Raymond W. Cohen to the RxSight Board of Directors,” said J. Andy Corley, Chairman of the Board at RxSight. “Ray’s extensive track record in leading and scaling medical technology companies will be invaluable as we advance our strategy and enter the next phase of growth. His insights and guidance will help us expand the reach of the RxSight® Light Adjustable Lens system, enabling more physicians and patients to benefit from truly customized vision after cataract surgery.”","length":504,"tagName":"p"},{"type":"text","content":"Mr. Cohen, an accredited public company director and accomplished medical technology executive, has over four decades of industry experience. He was the co-founder and chief executive officer of Axonics, Inc. (Nasdaq: AXNX) a global leader in implantable neuromodulation devices that completed its initial public offering in 2018. Under his leadership, Axonics generated over $1 billion in revenue within four years of its commercial launch, became profitable, earned recognition as the fastest-growing technology company in North America and was acquired by Boston Scientific in 2024 for $3.7 billion. In March 2025, Mr. Cohen, as chairman of SoniVie, Ltd., an Israeli clinical stage company, led the sale of that company to Boston Scientific for $600 million.","length":761,"tagName":"p"},{"type":"text","content":"“I see tremendous potential for RxSight to get back on its growth track by strengthening its position in the premium int...